REGENXBIO (NASDAQ:RGNX) Receives Buy Rating from HC Wainwright

REGENXBIO (NASDAQ:RGNX - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $36.00 price objective on the biotechnology company's stock. HC Wainwright's price target suggests a potential upside of 383.87% from the stock's current price.

A number of other equities research analysts have also weighed in on RGNX. Royal Bank of Canada restated an "outperform" rating and issued a $35.00 price objective on shares of REGENXBIO in a report on Wednesday, December 11th. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday, November 20th. Morgan Stanley reissued an "overweight" rating and issued a $22.00 target price on shares of REGENXBIO in a research note on Friday, November 15th. Raymond James restated an "outperform" rating and set a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. Finally, StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, September 20th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $35.27.

REGENXBIO Trading Up 5.5 %

Shares of RGNX traded up $0.39 during midday trading on Wednesday, reaching $7.44. The stock had a trading volume of 1,616,041 shares, compared to its average volume of 1,552,571. The company has a market capitalization of $368.61 million, a price-to-earnings ratio of -1.48 and a beta of 1.28. The company's 50-day moving average is $8.91 and its 200 day moving average is $10.56. REGENXBIO has a 12-month low of $6.56 and a 12-month high of $28.80.

Institutional Investors Weigh In On REGENXBIO

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 2,510 shares in the last quarter. FMR LLC raised its holdings in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,656 shares during the period. nVerses Capital LLC raised its position in shares of REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of REGENXBIO by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 3,720 shares in the last quarter. Finally, Arizona State Retirement System raised its position in shares of REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company's stock valued at $137,000 after buying an additional 1,997 shares during the last quarter. Institutional investors own 88.08% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.